Here we discuss challenges and opportunities highlighted by recent successes in drug development in schizophrenia, particularly the benefits of patient stratification to define patient subgroups most likely to respond to treatment.
Here we discuss challenges and opportunities highlighted by recent successes in drug development in schizophrenia, particularly the benefits of patient stratification to define patient subgroups most likely to respond to treatment.
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment.
